You are here

POC Study in Partially Responsive Generalized Anxiety Disorder

Last updated on November 14, 2019

FOR MORE INFORMATION
Study Location
Comprehensive Clinical Development, Inc.
Cerritos, California, 90703 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Generalized Anxiety Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Outpatient males and females 18 65 years of age (inclusive).

2. Diagnostic and Statistical Manual of Mental Disorders Fourth edition Text Revised (DSM
IV TR) diagnosis of GAD (DSM IV TR, 300.02), confirmed as primary diagnosis by the
Mini international neuropsychiatric interview (MINI) structured interview.

3. All subjects must have a total HAM A (via SIGH A) score 22 at screening. In addition,
scores at the baseline visit must also be within 20% of scores at screening.

4. Subjects must also have a Covi Anxiety Scale score of 9 and a Raskin Depression Scale
score 7 at the Screening (Visit 1) visit to ensure predominance of anxiety symptoms
over depression symptoms.

5. Taking an FDA approved GAD treatment (escitalopram 10 to 20 mg total daily dose,
paroxetine 20 to 50 mg total daily dose, duloxetine 60 to 120 mg total daily dose, or
venlafaxine 75 to 225 mg total daily dose) at a stable FDA approved dosage for at
least the two consecutive months in the current episode immediately prior to the
screening visit. Sertraline or citalopram are also permitted as background treatment
for GAD at doses of 50 to 200 mg total daily dose and 20 to 40 mg total daily dose,
respectively.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Subjects with a history of daily benzodiazepine use within one month of the screening
visit.

2. Recent (defined as meeting disorder diagnostic criteria during the last 6 months) of a
DSM IV TR Axis I diagnosis other than generalized anxiety disorder, with the following
exceptions: a. Subjects with recent (in the last 2 months) major depressive disorder
may be enrolled if the anxiety symptoms are predominant over the depressive symptoms,
as judged by the Covi/Raskin criteria listed above and confirmed GAD as the primary
diagnosis by the MINI structured interview. b. Comorbid social phobia and/or specific
phobias are permitted as long as the anxiety symptoms due to these disorders are
clinically less significant than the anxiety symptoms due to GAD and GAD is confirmed
as the primary diagnosis by the MINI structured interview.

3. Recent (defined as meeting disorder diagnostic criteria during the last 6 months) of a
DSM IV TR Axis I of panic disorder with or without agoraphobia, Post Traumatic Stress
Disorder (PTSD), dissociative disorder, obsessive compulsive disorder, attention
deficit disorder. If a subject has a past misdiagnosis of any of these disorders, or
if the subject has another psychiatric disorder that in the opinion of the
investigator affects the suitability of a subject for this study based on safety or
other considerations, the investigator will need to contact the sponsor prior to
screening.

4. Past and/or current DSM IV TR diagnosis of schizophrenia, schizoaffective disorder,
other psychotic disorders, bipolar disorders (I or II), factitious disorder or
cognitive disorder (including delirium, dementia, and amnestic disorder).

5. Presence of comorbid personality disorders (Axis II) based on DSM IV TR.

6. Subjects who meet DSM IV TR defined diagnostic criteria for psychoactive substance
dependence (excluding nicotine dependence) within 12 months of screening or DSM IV TR
defined substance abuse within 3 months prior to screening.

NCT02310568
Pfizer
Terminated
POC Study in Partially Responsive Generalized Anxiety Disorder

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE POC Study in Partially Responsive Generalized Anxiety Disorder
Official Title  ICMJE An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder
Brief SummaryThis study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel Comparison Design (SPCD). The study will use the Hamilton Anxiety Rating Scale (HAM-A) to measure change in symptoms from baseline for two doses of PF-06372865 compared to placebo.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Generalized Anxiety Disorder
Intervention  ICMJE Drug: PF-06372865.
Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
Study Arms  ICMJE
  • Experimental: PF 06372865 2.5 mg BID then placebo.
    PF 06372865 2.5 mg tablet 2 times daily for 4 weeks (Stage 1), followed by placebo 2 times daily for 4 weeks (Stage 2).
    Intervention: Drug: PF-06372865.
  • Experimental: PF 06372865 7.5 mg BID then placebo.
    PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 1), followed by placebo (2 times daily) for 4 weeks (Stage 2).
    Intervention: Drug: PF-06372865.
  • Experimental: Placebo then PF 06372865 2.5 mg BID.
    Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for 4 weeks
    Intervention: Drug: PF-06372865.
  • Experimental: Placebo then PF 06372865 7.5 mg BID.
    Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 2).
    Intervention: Drug: PF-06372865.
  • Placebo Comparator: Placebo followed by placebo.
    Placebo 2 times daily for 4 weeks (Stage 1) followed by Placebo 2 times daily for 4 weeks (Stage 2).
    Intervention: Drug: PF-06372865.
Publications *Targum SD, Murphy C, Khan J, Zumpano L, Whitlock M, Simen AA, Binneman B. Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder. Innov Clin Neurosci. 2018 Apr 1;15(3-4):37-42.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: December 11, 2015)
90
Original Estimated Enrollment  ICMJE
 (submitted: December 3, 2014)
384
Actual Study Completion Date  ICMJE October 2015
Actual Primary Completion DateOctober 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  1. Outpatient males and females 18 65 years of age (inclusive).
  2. Diagnostic and Statistical Manual of Mental Disorders Fourth edition Text Revised (DSM IV TR) diagnosis of GAD (DSM IV TR, 300.02), confirmed as primary diagnosis by the Mini international neuropsychiatric interview (MINI) structured interview.
  3. All subjects must have a total HAM A (via SIGH A) score 22 at screening. In addition, scores at the baseline visit must also be within 20% of scores at screening.
  4. Subjects must also have a Covi Anxiety Scale score of 9 and a Raskin Depression Scale score 7 at the Screening (Visit 1) visit to ensure predominance of anxiety symptoms over depression symptoms.
  5. Taking an FDA approved GAD treatment (escitalopram 10 to 20 mg total daily dose, paroxetine 20 to 50 mg total daily dose, duloxetine 60 to 120 mg total daily dose, or venlafaxine 75 to 225 mg total daily dose) at a stable FDA approved dosage for at least the two consecutive months in the current episode immediately prior to the screening visit. Sertraline or citalopram are also permitted as background treatment for GAD at doses of 50 to 200 mg total daily dose and 20 to 40 mg total daily dose, respectively.

Exclusion criteria:

  1. Subjects with a history of daily benzodiazepine use within one month of the screening visit.
  2. Recent (defined as meeting disorder diagnostic criteria during the last 6 months) of a DSM IV TR Axis I diagnosis other than generalized anxiety disorder, with the following exceptions: a. Subjects with recent (in the last 2 months) major depressive disorder may be enrolled if the anxiety symptoms are predominant over the depressive symptoms, as judged by the Covi/Raskin criteria listed above and confirmed GAD as the primary diagnosis by the MINI structured interview. b. Comorbid social phobia and/or specific phobias are permitted as long as the anxiety symptoms due to these disorders are clinically less significant than the anxiety symptoms due to GAD and GAD is confirmed as the primary diagnosis by the MINI structured interview.
  3. Recent (defined as meeting disorder diagnostic criteria during the last 6 months) of a DSM IV TR Axis I of panic disorder with or without agoraphobia, Post Traumatic Stress Disorder (PTSD), dissociative disorder, obsessive compulsive disorder, attention deficit disorder. If a subject has a past misdiagnosis of any of these disorders, or if the subject has another psychiatric disorder that in the opinion of the investigator affects the suitability of a subject for this study based on safety or other considerations, the investigator will need to contact the sponsor prior to screening.
  4. Past and/or current DSM IV TR diagnosis of schizophrenia, schizoaffective disorder, other psychotic disorders, bipolar disorders (I or II), factitious disorder or cognitive disorder (including delirium, dementia, and amnestic disorder).
  5. Presence of comorbid personality disorders (Axis II) based on DSM IV TR.
  6. Subjects who meet DSM IV TR defined diagnostic criteria for psychoactive substance dependence (excluding nicotine dependence) within 12 months of screening or DSM IV TR defined substance abuse within 3 months prior to screening.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02310568
Other Study ID Numbers  ICMJE B7431007
Has Data Monitoring CommitteeYes
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateSeptember 2016

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now